ID   NK-TY2
AC   CVCL_F0XV
RX   Patent=US7781210;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7865.
CC   Population: Japanese.
CC   Characteristics: IL2 dependent (Patent=US7781210).
CC   Doubling time: 72 hours (Patent=US7781210).
CC   Donor information: Although the patient was Epstein-Barr virus positive, the cell line is not.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: NK T-cell; CL=CL_0000814.
DI   NCIt; C4684; Nasal type extranodal NK/T-cell lymphoma
DI   ORDO; Orphanet_86879; Extranodal nasal NK/T cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 27-11-25; Last updated: 27-11-25; Version: 1
//
RX   Patent=US7781210;
RA   Tsuchiyama, Junjiro
RA   Yoshino, Tadashi
RA   Harada, Mine
RT   "Epstein-Barr virus-negative NK cell line.";
RL   Patent number US7781210, 24-Aug-2010.
//